Compare ANAB & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | AFYA |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2015 | 2019 |
| Metric | ANAB | AFYA |
|---|---|---|
| Price | $55.75 | $14.82 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | ★ $74.64 | $17.00 |
| AVG Volume (30 Days) | ★ 587.2K | 99.8K |
| Earning Date | 03-03-2026 | 03-12-2026 |
| Dividend Yield | N/A | ★ 4.44% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $10.11 |
| Revenue Next Year | $33.49 | $7.57 |
| P/E Ratio | ★ N/A | $9.30 |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $15.40 | $13.00 |
| 52 Week High | $68.39 | $19.76 |
| Indicator | ANAB | AFYA |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 55.89 |
| Support Level | $52.68 | $14.16 |
| Resistance Level | $57.70 | $15.50 |
| Average True Range (ATR) | 4.06 | 0.65 |
| MACD | -1.35 | 0.07 |
| Stochastic Oscillator | 8.37 | 65.14 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.